{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:25:39Z","timestamp":1790076339040,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":429,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1002\/pbc.25117","type":"journal-article","created":{"date-parts":[[2014,6,29]],"date-time":"2014-06-29T19:07:37Z","timestamp":1404068857000},"page":"1754-1760","source":"Crossref","is-referenced-by-count":51,"title":["A Phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group"],"prefix":"10.1002","volume":"61","author":[{"given":"Terzah M.","family":"Horton","sequence":"first","affiliation":[{"name":"Texas Children's Cancer and Hematology Centers at Baylor College of Medicine; Houston; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Perentesis","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center; Cincinnati; Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Gamis","sequence":"additional","affiliation":[{"name":"Children's Mercy Hospitals & Clinics; Kansas City; Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"Keck School of Medicine; University of Southern California; Los Angeles California"},{"name":"Children's Oncology Group-Operations Center; Monrovia; California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[{"name":"Children's Oncology Group-Operations Center; Monrovia; California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ballard","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of Kentucky; Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Adlard","sequence":"additional","affiliation":[{"name":"Children's Hospital of Orange County; Orange; California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna S.","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Wake Forest University; Winston-Salem NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin O.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology; Department of Internal Medicine; University of Cincinnati Cancer Institute; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaye","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Texas Children's Cancer and Hematology Centers at Baylor College of Medicine; Houston; Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel\u00e9","family":"Kelder","sequence":"additional","affiliation":[{"name":"Department of Hematology; VU University Medical Center; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit J.","family":"Schuurhuis","sequence":"additional","affiliation":[{"name":"Department of Hematology; VU University Medical Center; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Moscow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of Kentucky; Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,29]]},"reference":[{"key":"10.1002\/pbc.25117-BIB0001|pbc25117-cit-0001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2012.44.0958","article-title":"Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies","volume":"31","author":"Micel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0002|pbc25117-cit-0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: An expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem Biol"},{"key":"10.1002\/pbc.25117-BIB0003|pbc25117-cit-0003","first-page":"2119","article-title":"Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia","volume":"30","author":"Szczepanek","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1002\/pbc.25117-BIB0004|pbc25117-cit-0004","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0005|pbc25117-cit-0005","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/pbc.25117-BIB0006|pbc25117-cit-0006","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1002\/pbc.25117-BIB0007|pbc25117-cit-0007","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.25117-BIB0008|pbc25117-cit-0008","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0009|pbc25117-cit-0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25117-BIB0010|pbc25117-cit-0010","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1158\/1078-0432.CCR-07-4626","article-title":"Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia","volume":"14","author":"Attar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25117-BIB0011|pbc25117-cit-0011","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","article-title":"Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (alliance) study 10502","volume":"31","author":"Attar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0012|pbc25117-cit-0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25117-BIB0013|pbc25117-cit-0013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-006-0367-6","article-title":"Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status","volume":"60","author":"Minderman","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25117-BIB0014|pbc25117-cit-0014","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1073\/pnas.252462599","article-title":"Preferential induction of apoptosis for primary human leukemic stem cells","volume":"99","author":"Guzman","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/pbc.25117-BIB0015|pbc25117-cit-0015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25117-BIB0016|pbc25117-cit-0016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0017|pbc25117-cit-0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/107327480401100216","article-title":"Considerations for targeting malignant stem cells in leukemia","volume":"11","author":"Guzman","year":"2004","journal-title":"Cancer Control"},{"key":"10.1002\/pbc.25117-BIB0018|pbc25117-cit-0018","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.25117-BIB0019|pbc25117-cit-0019","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ni1080","article-title":"Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity","volume":"5","author":"Hope","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1002\/pbc.25117-BIB0020|pbc25117-cit-0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/biot.201100350","article-title":"Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance","volume":"7","author":"Hoang","year":"2012","journal-title":"Biotechnol J"},{"key":"10.1002\/pbc.25117-BIB0021|pbc25117-cit-0021","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"key":"10.1002\/pbc.25117-BIB0022|pbc25117-cit-0022","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2012.05.024","article-title":"Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells","volume":"11","author":"Ashton","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1002\/pbc.25117-BIB0023|pbc25117-cit-0023","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1001\/jama.2010.1862","article-title":"Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia","volume":"304","author":"Gentles","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/pbc.25117-BIB0024|pbc25117-cit-0024","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0025|pbc25117-cit-0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","article-title":"Leukemia stem cells and microenvironment: Biology and therapeutic targeting","volume":"29","author":"Konopleva","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0026|pbc25117-cit-0026","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","article-title":"High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival","volume":"11","author":"van Rhenen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25117-BIB0027|pbc25117-cit-0027","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2005-06-2325","article-title":"AML engraftment in the NOD\/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML","volume":"107","author":"Pearce","year":"2006","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0028|pbc25117-cit-0028","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1200\/JCO.2004.12.185","article-title":"Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study (ADVL0015)","volume":"22","author":"Blaney","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0029|pbc25117-cit-0029","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group Study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25117-BIB0030|pbc25117-cit-0030","first-page":"9537","article-title":"A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory\/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) Study [abstract]","volume":"28","author":"Horton","year":"2010","journal-title":"Proc ASCO"},{"key":"10.1002\/pbc.25117-BIB0031|pbc25117-cit-0031","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0032|pbc25117-cit-0032","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0033|pbc25117-cit-0033","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2307\/2533268","article-title":"Incorporating toxicity considerations into the design of two-stage phase II clinical trials","volume":"51","author":"Bryant","year":"1995","journal-title":"Biometrics"},{"key":"10.1002\/pbc.25117-BIB0034|pbc25117-cit-0034","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2003.06.128","article-title":"Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951","volume":"21","author":"Wells","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0035|pbc25117-cit-0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/pbc.24398","article-title":"Phase I\/II trial of clofarabine and cytarabine in children with relapsed\/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group","volume":"60","author":"Cooper","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25117-BIB0036|pbc25117-cit-0036","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0037|pbc25117-cit-0037","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: Results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25117-BIB0038|pbc25117-cit-0038","article-title":"How I treat pediatric relapsed acute myeloid leukemia","author":"Kaspers","journal-title":"Br J Haematol."},{"key":"10.1002\/pbc.25117-BIB0039|pbc25117-cit-0039","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","article-title":"Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma","volume":"107","author":"Miyakoshi","year":"2006","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0040|pbc25117-cit-0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10428190600988010","article-title":"Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone","volume":"48","author":"Chew","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1002\/pbc.25117-BIB0041|pbc25117-cit-0041","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0042|pbc25117-cit-0042","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25117-BIB0043|pbc25117-cit-0043","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI68101","article-title":"Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity","volume":"124","author":"Kagoya","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1002\/pbc.25117-BIB0044|pbc25117-cit-0044","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/leu.2013.366","article-title":"Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia","volume":"28","author":"Koyama","year":"2013","journal-title":"Leukemia"},{"key":"10.1002\/pbc.25117-BIB0045|pbc25117-cit-0045","doi-asserted-by":"crossref","first-page":"e75280","DOI":"10.1371\/journal.pone.0075280","article-title":"Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells","volume":"8","author":"Manni","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1002\/pbc.25117-BIB0046|pbc25117-cit-0046","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-12-3134","article-title":"Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors","volume":"19","author":"Tagoug","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25117-BIB0047|pbc25117-cit-0047","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-12-1511","article-title":"Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K\/AKT, and NF-kappaB","volume":"19","author":"Bastian","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25117-BIB0048|pbc25117-cit-0048","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2Rgammac-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1002\/pbc.25117-BIB0049|pbc25117-cit-0049","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1002\/pbc.25117-BIB0050|pbc25117-cit-0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25117","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pbc.25117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T11:29:38Z","timestamp":1625398178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25117"}},"subtitle":["Bortezomib With Reinduction in Pediatric AML"],"short-title":[],"issued":{"date-parts":[[2014,6,29]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25117","relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6,29]]}}}